What is the ticker symbol for Johnson & Johnson?

Johnson & Johnson trades as JNJ on the NYSE.

What are Johnson & Johnson's marketed drugs?

Top marketed products include Darzalex, Stelara, Remicade, Invega Sustenna, Tremfya, Erleada.

Johnson & Johnson (JNJ)

NYSE 59 marketed · 48 in Phase 3

Quick facts

Ticker	JNJ (NYSE)

Marketed products

Darzalex · Oncology · revenue 11800
Daratumumab binds CD38 on tumor cells, inducing apoptosis and immune-mediated lysis via CDC, ADCC, and ADCP.
Stelara · Immunology · revenue 9500
Ustekinumab binds to the p40 subunit of IL-12 and IL-23, disrupting their signaling and reducing inflammation.
Remicade · Oncology · revenue 4200
Remicade works by binding to and neutralizing tumor necrosis factor, a protein that promotes inflammation and tissue damage.
Invega Sustenna · Metabolic · revenue 3800
Invega Sustenna works by blocking a specific channel in the brain that helps regulate electrical activity.
Tremfya · Immunology · revenue 3600
Guselkumab binds to IL-23's p19 subunit, blocking its interaction with the IL-23 receptor and inhibiting proinflammatory cytokine release.
Erleada · Oncology · revenue 2600
Erleada blocks the androgen receptor, a protein that helps cancer cells grow.
Zytiga · Oncology · revenue 1500
Zytiga blocks the production of male hormones that fuel prostate cancer growth.
Carvykti · Oncology · revenue 1100
Rybrevant · Oncology · revenue 800
Amivantamab-vmjw targets EGFR and MET, disrupting their signaling and enhancing immune cell-mediated destruction of tumor cells.
Invokana · Metabolic · revenue 800
Invokana works by blocking the SGLT2 protein in the kidneys to reduce glucose reabsorption.
Spravato · Metabolic · revenue 800
Spravato works by blocking the action of glutamate, a neurotransmitter involved in mood regulation.
Sirturo · Infectious Disease · revenue 400
Sirturo works by blocking the potassium voltage-gated channel subfamily H member 2, which is essential for the survival of Mycobacterium tuberculosis bacteria.
Talvey · Oncology · revenue 400
Talquetamab binds to the T-cell surface glycoprotein CD3, triggering a response that kills cancer cells.
Bcmaxcd3 · Oncology · revenue 400
Teclistamab-cqyv activates T-cells by binding to CD3 and BCMA, leading to the lysis of multiple myeloma cells.
Balversa · Oncology · revenue 300
Balversa works by blocking the fibroblast growth factor receptor 1, a protein that helps cancer cells grow and spread.
Reopro · Cardiovascular
Axert · Neuroscience
Axert works by binding to serotonin receptors in the brain to relieve migraine pain.
RYBREVANT · Oncology
Antidepressant · Neuroscience
Apixaban 2.5 mg
Atomoxetine (ATO) · Psychiatry / Neurology
Atomoxetine selectively inhibits the reuptake of norepinephrine in the central nervous system, increasing norepinephrine availability at synapses.
Canagliflozin, 100 mg
Canagliflozin 300 mg
Abiraterone Acetate · Oncology
Abiraterone Acetate blocks the production of androgens, which are hormones that prostate cancer cells need to grow.
Parafon Forte Dsc · Pain
Cilta-cel
Cosentyx · Immunology
Prezista · Immunology
Darunavir works by blocking the protease enzyme, which is essential for the replication of the HIV virus.
Dexamethasone 20 mg
Synestrol · Other
Benadryl · Neuroscience
Motilium · Cardiovascular
Esketamine 56 mg
Intelence · Immunology
Intelence works by blocking the reverse transcriptase enzyme, which is essential for the replication of the HIV virus.
Duragesic · Oncology
Synthetic opioid 50-100x more potent than morphine that binds mu-opioid receptors, providing potent analgesia and anesthesia.
Razadyne · Neuroscience
Razadyne works by blocking the enzyme that breaks down acetylcholine, allowing more of this neurotransmitter to be available in the brain.
Grifulvin V · Infectious Disease
GRIFULVIN V · Dermatology
Haldol · Neuroscience
Haldol · Neuroscience

Phase 3 pipeline

5-Flurouracil · Oncology
5-Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase and gets incorporated into RNA and DNA, disrupting nucleotide synthesis and causing cell death.
Abiraterone Acetate (AA) · Oncology
Abiraterone acetate inhibits CYP17A1, a key enzyme in androgen synthesis, thereby reducing testosterone production in patients with castration-resistant prostate cancer.
Abiraterone acetate and prednisone · Oncology
Abiraterone acetate inhibits CYP17A1 to block androgen synthesis, while prednisone suppresses ACTH-driven compensatory steroid production in castration-resistant prostate cancer.
Active reference comparator
Unable to determine specific mechanism without drug identity.
Amivantamab Intravenous · Oncology
Amivantamab is a bispecific monoclonal antibody that simultaneously binds to EGFR and MET receptors, blocking their signaling and triggering immune-mediated tumor cell death.
Antihyperglycemic agent(s) · Endocrinology / Diabetes
Antihyperglycemic agents work by reducing blood glucose levels through various mechanisms such as enhancing insulin secretion, improving insulin sensitivity, or reducing hepatic glucose production.
BCG Vesiculture · Oncology
BCG Vesiculture is a live attenuated Bacillus Calmette-Guérin vaccine formulation designed to stimulate innate and adaptive immune responses against bladder cancer.
Best Supportive Care (BSC)
Best Supportive Care (BSC) is a control or comparator arm in clinical trials that provides standard medical management and symptom relief without the investigational drug.
Dapoxetine hydrochloride · Urology / Sexual Health
Dapoxetine is a short-acting selective serotonin reuptake inhibitor (SSRI) that increases serotonin levels in the central nervous system to delay ejaculation.
Dara IV · Oncology
Daratumumab is a monoclonal antibody that binds to CD38 on the surface of multiple myeloma cells, triggering their destruction through multiple immune mechanisms.
Dara SC · Oncology
Dara SC (daratumumab subcutaneous) is a monoclonal antibody that targets CD38 on multiple myeloma cells, triggering their destruction through multiple immune mechanisms.
Daratumumab IV · Oncology
Daratumumab is a monoclonal antibody that binds to CD38 on the surface of multiple myeloma cells, triggering their destruction through multiple immune mechanisms.
Daratumumab SC · Oncology
Daratumumab is a monoclonal antibody that binds to CD38 on multiple myeloma cells, triggering their destruction through multiple immune mechanisms.
Daratumumab SC: daratumumab + rHuPH20 · Oncology
Daratumumab is a monoclonal antibody that binds to CD38 on multiple myeloma cells and triggers their destruction through multiple immune mechanisms, while rHuPH20 enhances subcutaneous bioavailability.
DRV/COBI FDC · Infectious Disease
DRV/COBI is a fixed-dose combination of darunavir (a protease inhibitor) and cobicistat (a pharmacokinetic booster) that inhibits HIV protease to prevent viral replication.
epoetin alfa + packed RBC transfusion · Oncology
Epoetin alfa stimulates erythropoiesis by binding to the erythropoietin receptor, promoting the production of red blood cells.
ExPEC9V · Immunology / Infectious Disease
ExPEC9V is a vaccine designed to stimulate immune responses against extraintestinal pathogenic E. coli (ExPEC) strains.
Genetic: AAV5-hRKp.RPGR · Ophthalmology / Rare Genetic Disorders
AAV5-hRKp.RPGR is a gene therapy that delivers a functional copy of the RPGR gene into retinal cells to restore vision in patients with X-linked retinitis pigmentosa.
Genetic: AAV5-hRKp.RPGR Intermediate Dose · Ophthalmology / Retinal Diseases
AAV5-hRKp.RPGR is a gene therapy that delivers a functional copy of the RPGR gene into retinal cells to restore vision in patients with X-linked retinitis pigmentosa.
Genetic: AAV5-hRKp.RPGR Low Dose · Ophthalmology / Retinal Genetic Disorders
AAV5-hRKp.RPGR is a gene therapy that delivers a functional copy of the RPGR gene into retinal cells to restore vision in patients with X-linked retinitis pigmentosa.
Guselkumab Dose 1 · Immunology/Dermatology
Guselkumab is a monoclonal antibody that selectively blocks interleukin-23 (IL-23) signaling to reduce inflammatory immune responses.
Guselkumab Intravenous
Guselkumab Subcutaneous · Immunology / Dermatology
Guselkumab is a monoclonal antibody that selectively blocks interleukin-23 (IL-23) signaling to reduce inflammatory immune responses.
HD quadrivalent influenza vaccine · Immunology / Infectious Disease
HD quadrivalent influenza vaccine stimulates immune responses against four strains of influenza virus using a high-dose antigen formulation to enhance protection, particularly in older adults.
JNJ-77242113 · Neurology/Psychiatry
JNJ-77242113 is a selective inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular signaling in the brain to modulate neuronal activity.
JNJ-79635322 · Immunology
JNJ-79635322 is a monoclonal antibody that targets and inhibits IL-17A, a pro-inflammatory cytokine involved in immune-mediated inflammatory diseases.
Leucovorin calcium/Levoleucovorin · Oncology
Leucovorin calcium and levoleucovorin are reduced folate cofactors that enhance the efficacy of antimetabolite chemotherapy agents by providing essential one-carbon units for nucleotide synthesis.
Matching Placebo to JNJ-77242113
This is a placebo control formulation matching the inactive vehicle and appearance of JNJ-77242113 for blinded clinical trial comparison.
Matching placebo to Quetiapine XR · Psychiatry
This is a matching placebo formulation designed to mimic Quetiapine XR (an atypical antipsychotic) for blinded clinical trial purposes.
Matching placebo to Seltorexant · Neurology
This is a matching placebo control formulation designed to mimic Seltorexant, an orexin 2 receptor antagonist used in sleep disorder trials.
Matching Placebo to Ustekinumab
This is a placebo formulation designed to match the appearance and administration route of ustekinumab for blinded clinical trial comparison.
Metformin immediate release · Diabetes
Metformin reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK) and inhibiting mitochondrial complex I.
Nipocalimab SC-LIV · Immunology
Nipocalimab is a subcutaneous monoclonal antibody that blocks neonatal Fc receptor (FcRn) to reduce pathogenic immunoglobulin levels in autoimmune conditions.
PCI-32765 (Ibrutinib) · Oncology
Ibrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK) that blocks B-cell receptor signaling and reduces proliferation of malignant B cells.
Placebo (20% Intralipid)
Placebo (20% Intralipid) does not have an active pharmacological effect; it serves as a control in clinical trials.
Placebo and prednisone · Immunology
This is a comparator arm combining placebo with prednisone, a corticosteroid that suppresses immune function and reduces inflammation.
Placebo for guselkumab
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.
Placebo for Niraparib · Oncology
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.
PP1M · Neurology/Psychiatry
PP1M is a phosphodiesterase 10 (PDE10) inhibitor that increases intracellular cyclic nucleotide levels to modulate neuronal signaling.
PP6M injection Dose 1 · Contraception / Women's Health
PP6M is a long-acting injectable contraceptive that prevents pregnancy through hormonal suppression of ovulation.

Phase 2 pipeline

AAV5-hRKp.RPGR · Ophthalmology
AAV5-hRKp.RPGR is a gene therapy that delivers a functional copy of the RPGR gene into retinal cells to restore vision in patients with X-linked retinitis pigmentosa.
AL-335
Amivantamab IV · Oncology
Targeting EGFR
Amivantamab SC · Oncology
Amivantamab SC is a fully human bispecific antibody that targets and blocks the activity of the EGFR and MET receptors.
ARV Background Regimen
Bermekimab Monoclonal Antibody · Immunology
Bermekimab is a monoclonal antibody that blocks IL-1β, a key pro-inflammatory cytokine, to reduce inflammation and immune activation.
Bridging Therapy
Chemotherapy: Pemetrexed
CNTO 2476 3.0 x 10^5 cells
CNTO 6785
Concerta AG formulation · Neurology
Methylphenidate acts as a norepinephrine-dopamine reuptake inhibitor.
Concerta EG formulation · Neurology
Methylphenidate acts as a norepinephrine-dopamine reuptake inhibitor.
CV-18C3
JNJ-61393215
JNJ-63723283
JNJ-64565111 Dose Level 1
JNJ-64565111 Dose Level 2
JNJ-64565111 Dose Level 3
JNJ-67953964
JNJ-68284528
JNJ-78934804
JNJ-81201887
JNJ-88545223
JNJ-89495120
JNJ-95475939
JNJ-95597528
M281
MABp1
NNC 0142-0000-0002
NNC0142-0002
Other Antibiotics
Part 1: Daratumumab
PegIFN-alpha2a
Prophylaxis A
Prophylaxis B
Prophylaxis C
RA-18C3
T2-18C3 therapeutic antibody

Phase 1 pipeline

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: